At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
NanoPac®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
In Brief
A Phase 2 clinical trial evaluating NanoPac® for Pancreatic Mucinous-Cystic Neoplasm. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
This study will evaluate intracystic NanoPac® (Sterile Nanoparticulate Paclitaxel) administered via endoscopic ultrasound-guided fine needle injection (EUS-FNI) in subjects with mucinous cystic pancreatic neoplasms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Mucinous-Cystic Neoplasm
CountriesUnited States
CollaboratorsUS Biotest, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartSep 2017
Primary CompletionJun 2020
TodayJul 2026
First PostedJun 16, 2017
Enrollment StartSep 29, 2017
Primary CompletionJun 29, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 9.0 years ago
Interventions
NanoPac®drug
NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)